7月12日，位于内蒙古自治区鄂尔多斯市的中核集团"国铀一号"示范工程顺利生产出第一桶铀产品，标 志着我国天然铀生产取得突破，将有力保障我国能源资源安全的自主可控。 目前，我国在运、在建核电机组总规模居世界第一。"国铀一号"技术将全面应用、加速推广到松辽、二 连、鄂尔多斯、伊犁等我国北方盆地铀资源开发，支撑建成一批新的铀矿大基地，全面保障核能发展对 铀资源的需求。 据中国核工业集团有限公司官网，中核集团是中央直接管理的特大型国有重要骨干企业，是国家核科技 工业主体，是推进核能开发利用、核工程建设、核技术应用的国家队和主力军，拥有完整的核科技工业 体系，肩负着推动国防建设和经济社会发展的双重使命。 中核集团党组成员、总会计师王学军6月6日表示，2024年，中核集团旗下上市公司市值合计约2600亿 元，全年增幅超过30%。 王学军在当日于南京举办的中核集团第三届上市公司集中投资者交流季活动上说，中核集团高度重视控 股上市公司市场价值表现。 从中核集团旗下上市公司具体表现来看，中国核电顺利完成2024年A股140亿元再融资项目；中国核建 持续强化核电建造能力，积极开拓国际市场，高质量完成国际热核聚变实验堆（ITER） ...

7月12日，位于内蒙古自治区鄂尔多斯市的中核集团"国铀一号"示范工程顺利生产出第一桶铀产品，标志着我国天然铀生产取得突破，将有力保障我国能 源资源安全的自主可控。 "国铀一号"示范工程是我国产能最大、建设标准最高、技术水平最先进的天然铀产能基地。项目于2024年7月12日开工建设，一年时间即生产出产品，创下国内天 然铀产能项目建设"新速度"。 天然铀是重要的战略资源和能源矿产，铀资源勘查采冶位于核燃料循环体系的前端，是核工业发展的重要物质基础。作为我国核地矿事业发展70年来规模最大的天 然铀产能项目，该项目第一桶铀成功下线，标志着我国铀资源开发迈入绿色安全、智能高效的新阶段，建成后将为国家能源安全与核工业发展提供坚实的资源保 障，同时也将大幅度提升我国天然铀产业的国际竞争力。 "'国铀一号'示范工程是我国第三代铀矿采冶技术体系的重大实践成果。它构建了以'绿色环保、远程管控、智能分析、高质高效'为核心的现代化铀矿山生产要素，成 功打造了新一代的智慧矿山标杆。通过采矿全流程的数字化与智能化分析，实现了铀矿开采的可预测、可控制。"中国铀业股份有限公司党委书记、董事长袁旭表 示。 在上市公司取得良好业绩的同时，中核集 ...

Group 1 - Chengdu High-tech Zone Medical Device Innovation and Transformation Association facilitated Qinglan Jichuang Medical Equipment to obtain a credit line of tens of millions from Chengdu Bank, specifically for production line expansion and technology research and development [1] - Anbiping announced that its HPV nucleic acid test kit received a medical device registration certificate from the National Medical Products Administration, capable of detecting 18 high-risk HPV types and further expanding its layout in the tumor screening field [1] - In the first half of 2025, China approved 45 innovative medical devices, a year-on-year increase of 87%, reflecting the continuous policy dividends driving industry technological upgrades [1] Group 2 - The domestic nuclear medicine industry has a high dependence on imported radionuclide raw materials, but domestic technological breakthroughs and capacity releases are expected to enhance the self-supply capability of major isotopes [2] - The nuclear medicine regulatory environment is strict, creating high barriers to entry, with companies like China Radiopharmaceuticals and Dongcheng Pharmaceutical holding a first-mover advantage in the midstream production and distribution sectors [2] - The nuclear medicine market is projected to grow at a compound annual growth rate of over 20% over the next five years, reaching 26 billion yuan by 2030, driven by policy support and increasing medical resource allocation [2] Group 3 - The ChiNext Medical ETF tracks the Chuangyi Medicine Index, which can experience daily fluctuations of up to 20%, reflecting the overall performance of listed companies in the medical manufacturing, medical devices, and medical services sectors on the ChiNext market [2] - The index consists of companies with innovative characteristics and high growth potential, generally characterized by high research and development investment and industry development potential [2]

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1]. Core Viewpoints - The nuclear medicine market is expected to grow significantly, with a projected global market size of USD 10.65 billion in 2023, reaching USD 31.44 billion by 2033, indicating a compound annual growth rate (CAGR) of 11.45% from 2024 to 2033 [4][19]. - The rise of Radionuclide Drug Conjugates (RDC) is a key driver for the nuclear medicine industry, with notable products like Pluvicto showing strong sales performance, achieving USD 1.392 billion in revenue in 2024, a 42% increase [19][22]. - China's nuclear medicine market is expected to grow from CNY 22 billion in 2017 to CNY 93 billion by 2025, with a CAGR of 32.4%, and further to CNY 260 billion by 2030, maintaining a high growth rate of 22.7% [26][28]. Summary by Sections Industry Overview - The closing index for the industry is 7754.01, with a 52-week high of 8490.25 and a low of 6070.89 [1]. Market Dynamics - The nuclear medicine sector is characterized by high barriers to entry and strong regulatory oversight, with significant advantages for companies with a comprehensive industry chain layout [6][29]. - The domestic nuclear medicine application level is significantly lower than that of developed countries, with a market primarily composed of traditional generic nuclear drugs [5][24]. Key Companies and Financial Projections - China Isotope & Radiation Corporation (1763.HK) and East China Pharmaceutical (002675.SZ) are leading players in the market, with extensive nuclear pharmacy networks and product pipelines [49][50]. - The financial performance of key companies indicates a robust growth trajectory, with China Isotope achieving a revenue of CNY 75.75 billion in 2024, and East China Pharmaceutical reporting CNY 10.12 billion in nuclear medicine revenue [49][50]. Regulatory Environment - Recent policies have been implemented to promote the development of the nuclear medicine industry, including the "Long-term Development Plan for Medical Isotopes (2021-2035)" which aims to enhance technology research and industry growth [26][27]. Future Outlook - The increasing focus on nuclear medicine, particularly in the context of precision therapy, is expected to drive further investment and innovation in the sector, with more domestic products anticipated to enter the market [19][24].

Core Viewpoint - Xiantong Pharmaceutical is preparing for an IPO on the Hong Kong Stock Exchange, focusing on the development and commercialization of radiopharmaceuticals, but faces significant competition and market challenges [1][2]. Company Overview - Xiantong Pharmaceutical is one of the earliest companies in China engaged in nuclear drug research and development, having previously listed on the New Third Board in 2016 [1]. - The company is the first in China to receive approval for innovative radiopharmaceuticals and has completed clinical trials for therapeutic radioligands [1][2]. Market Position and Competition - The core diagnostic drug, Oweining®, is facing intense competition shortly after its launch, with a narrowing "blue ocean" window [1][4]. - The therapeutic pipeline is crowded with targets such as SSTR and PSMA, with strong competitors like Novartis and Dongcheng [1][7]. - The nuclear pharmacy resources are dominated by major players, controlling 94% of the market, making it difficult for Xiantong to establish its own [1][9]. Financial Performance - In 2023 and 2024, Xiantong achieved revenues of 10.232 million and 44.064 million yuan, respectively, with product sales contributing minimally [3][4]. - The company reported losses of 309 million yuan in 2023 and 156 million yuan in 2024 [3]. Research and Development Pipeline - Xiantong has 15 pipeline assets, with two products, XTR008 and XTR012, expected to receive NDA and ANDA approvals by 2026 [2][5]. - The pipeline includes several diagnostic radiopharmaceuticals, with increasing competition in the domestic market [5][6]. Industry Trends - The global market for radiopharmaceuticals is evolving, with a shift towards therapeutic applications, projected to dominate the market by 2030 [7]. - The construction of nuclear pharmacies is capital-intensive and time-consuming, creating barriers for new entrants [9]. Investor Sentiment - Prior to the IPO application, several investors exited their positions, raising concerns about the company's stability and future prospects [10][11].

智通财经APP获悉，港股恒生指数跌0.12%，跌28点，报23864点；恒生科技指数涨0.15%。港股早盘成 交1309亿港元。 潼关黄金(00340)涨超5%，公司两个矿场内生动能强劲，黄金产量有望持续提升。 香港即将就数字资产的发展发表第二份政策宣言，阐述下一步的政策愿景和方向。稳定币概念板块全线 走高。众安在线(06060)涨10%；连连数字(02598)涨10%；联易融科技-W(09959)涨10%；移卡(09923)涨 7%。 内房股早盘普涨，广州拟优化房地产政策，全面取消限购、限售、限价。金辉控股(09993)涨65%，金地 置业（00535）涨18%；富力地产(02777)涨10%，融创中国(01918)涨7%。 山东墨龙(00568)再涨超33%，上一交易日飙升逾75%，中东冲突升级带动油价大涨。 金山软件(03888)涨超10%，下月将推出《解限机》，大摩料新游表现有望成股价关键推动力。 中国同辐(01763)涨超6%，中国成功实现商用堆生产钇-90，公司为中核集团控股子公司。 中国内地个人奢侈品市场加速增长，奢侈品网络营销全面进化。奢侈品品牌股涨幅居前 ，英皇钟表珠 宝(00887)涨10 ...

Core Viewpoint - The rapid growth of the "Technology Board" in China's bond market since May highlights the importance of technology in advancing Chinese modernization, with various market participants actively supporting innovation financing [2][3]. Group 1: Market Development - The "Technology Board" aims to address long-standing financing challenges in critical sectors such as semiconductors, quantum computing, and biomedicine, representing a breakthrough in financial supply-side structural reform [3]. - The issuance of technology bonds is not new, but the recent developments expand the scope of issuers and the use of raised funds, introducing innovative settings and regulations for more niche areas [3][4]. Group 2: Company Initiatives - The company has significantly increased its support for technology bond issuance, with over 2,700 billion yuan in underwriting for technology bonds in 2024, positioning itself among the market leaders [4]. - The company has facilitated the issuance of various pioneering technology bonds, including the first exchangeable company bond in Guangdong and the first public REIT for private industrial park infrastructure in China [4]. Group 3: Investment and Market Ecosystem - Following the rapid issuance of representative technology bonds, institutions are focusing on secondary market activities, enhancing their roles as investors and market makers, which creates new opportunities for development [6]. - The company utilizes digital tools to enhance pricing systems for technology bonds, improving liquidity and matching suitable investors with issuers [6][7]. Group 4: Future Outlook - The company anticipates that technology bonds will become a core financial tool supporting technological innovation, with ongoing efforts to align with national strategies and explore sustainable paths for risk-sharing and profit-sharing [8].

Major Events - JiuTai Rural Commercial Bank (06122) plans to sell 78.51% stake in HuanShan HuiMin Village Bank for 40.4 million yuan [1] - Vanke Enterprises (02202) intends to receive a loan of up to 3 billion yuan from its major shareholder, Shenzhen Metro Group [1] - China Gas Holdings (08246) signed a memorandum of understanding with the Lao Ministry of Industry and Commerce to explore cooperation in developing fuel and natural gas supply networks in Laos [1] - Miniso Group (09896) is conducting a preliminary assessment on the potential spin-off listing of its trendy toy business operated under the "TOP TOY" brand [1] - Baiyunshan Pharmaceutical (00874) subsidiary received approval from the National Medical Products Administration for the drug registration certificate of Tadalafil tablets (2.5mg, 5mg) [1] - Huaxing Capital Holdings (01911) portfolio company Circle successfully listed on the New York Stock Exchange, marking the first IPO milestone in the global stablecoin sector [1] - China National Nuclear Corporation (01763) plans to initiate its first irradiation station cooperation project in Peru [1] Operating Performance - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 50.7 billion yuan in the first five months, an increase of about 26.5% year-on-year [1] - China Overseas Land & Investment (00688) recorded a cumulative property sales amount of approximately 90.4 billion yuan in the first five months, a decrease of 11.1% year-on-year [1] - Shimao Group (00813) reported a cumulative contract sales total of 11.2 billion yuan in the first five months, a decrease of 18.71% year-on-year [1] - Zhongliang Holdings (02772) achieved a cumulative contract sales amount of approximately 5.37 billion yuan in the first five months, a decrease of 33.38% year-on-year [1] - GAC Group (02238) experienced a year-on-year decline in May's automobile production by 8.16% and a sales drop of 24.80% [1] - Poly Property Group (00119) achieved a contract sales amount of approximately 21.8 billion yuan in the first five months, an increase of 3.81% year-on-year [1] - New天绿色能源 (00956) completed a power generation volume of approximately 7.29 million megawatt-hours in the first five months, an increase of 10.86% year-on-year [1]

Core Viewpoint - The management of state-owned enterprises (SOEs) in China has shifted from policy advocacy to substantive implementation, with expectations for valuation restructuring and market confidence enhancement as assessment mechanisms and supporting policies improve [1][5]. Group 1: SOE Value Management - The State-owned Assets Supervision and Administration Commission (SASAC) has emphasized improving the quality of SOEs' listed companies and enhancing value management to stabilize market expectations [1][4]. - Several SOEs have held performance briefings and investor engagement activities, committing to increase dividend payouts and enhance shareholder returns while focusing on core business improvement and innovation [1][2]. - China National Nuclear Corporation (CNNC) reported a market value of approximately 260 billion yuan, with a year-on-year increase of over 30%, highlighting its commitment to shareholder value through strategic investments [1][2]. Group 2: Dividend Policies - China National Power has maintained a cash dividend payout ratio exceeding 35% for ten consecutive years, with the 2024 dividend ratio reaching a historical high of 41.92%, totaling over 24 billion yuan in cumulative dividends [2]. - China Nuclear Technology has consistently returned cash dividends for 18 years, with a 2024 payout ratio of 32.43% and an average payout ratio exceeding 30% from 2020 to 2024 [2]. - China Huaneng Group is focused on enhancing dividend frequency and amounts across its listed companies to stabilize market value [2]. Group 3: Innovation and Reform - Accelerating innovation and deepening reforms are crucial for SOEs to enhance value management and improve the quality of listed companies [3][4]. - The State Grid Corporation is implementing multiple measures to promote high-quality development of its listed companies, focusing on energy transition and new power system construction [3]. - China Aerospace Science and Technology Corporation aims to enhance innovation capabilities and integrate technology and industry innovation to improve value creation [3]. Group 4: Regulatory Framework - The SASAC has issued guidelines to improve the market value management of SOEs, emphasizing the importance of maintaining investor rights and promoting healthy capital market development [3][4]. - Recent analyses indicate that value management is essential for listed companies to enhance intrinsic value and market performance through various compliant methods [4][5]. - SOEs are increasingly formalizing their value management practices, including the establishment of value enhancement plans and regular communication with investors [5].

Group 1 - The core viewpoint is that China National Nuclear Corporation (CNNC) expects a market capitalization of approximately 260 billion yuan for its listed companies in 2024, with an annual growth rate exceeding 30% [1] - CNNC emphasizes the importance of market value performance for its listed companies, with several achieving an A-grade in information disclosure assessments from stock exchanges in 2024 [1] - China Nuclear Power successfully completed a 14 billion yuan refinancing project for A-shares in 2024 [1] Group 2 - China Nuclear Construction is enhancing its nuclear power construction capabilities and actively expanding into international markets, achieving significant milestones in the International Thermonuclear Experimental Reactor (ITER) project [1] - Tongfang Co. is focusing on strategic leadership and innovation, resulting in significant market development achievements and continuous growth in overseas revenue [1] - China Isotope & Radiation is deepening its "6+N" industry layout strategy, forming a collaborative ecosystem in core businesses such as nuclear medicine and irradiation technology applications [1] Group 3 - CNNC's overall performance is steadily improving, having received an A-grade in annual performance assessments from the State-owned Assets Supervision and Administration Commission for 19 consecutive years [2] - The year 2025 marks the 70th anniversary of China's nuclear industry and is designated as CNNC's "Pursuit of Excellence Year," aiming to support high-quality development of its listed companies through excellent operational performance and management efficiency [2] - CNNC plans to leverage capital market functions to assist in industrial transformation and upgrading, promoting high-level circulation of technology, industry, and finance [2]